CVAC vs. VTYX, SDGR, AMPH, SUPN, PCRX, HRMY, BLU, AMLX, BHC, and MORF
Should you be buying CureVac stock or one of its competitors? The main competitors of CureVac include Ventyx Biosciences (VTYX), Schrödinger (SDGR), Amphastar Pharmaceuticals (AMPH), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Harmony Biosciences (HRMY), BELLUS Health (BLU), Amylyx Pharmaceuticals (AMLX), Bausch Health Companies (BHC), and Morphic (MORF). These companies are all part of the "pharmaceutical preparations" industry.
CureVac vs.
CureVac (NASDAQ:CVAC) and Ventyx Biosciences (NASDAQ:VTYX) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, community ranking, analyst recommendations, risk and institutional ownership.
95.6% of Ventyx Biosciences shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Comparatively, 24.4% of Ventyx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
CureVac's return on equity of 0.00% beat Ventyx Biosciences' return on equity.
In the previous week, CureVac had 4 more articles in the media than Ventyx Biosciences. MarketBeat recorded 7 mentions for CureVac and 3 mentions for Ventyx Biosciences. Ventyx Biosciences' average media sentiment score of 0.90 beat CureVac's score of 0.37 indicating that Ventyx Biosciences is being referred to more favorably in the news media.
Ventyx Biosciences has lower revenue, but higher earnings than CureVac.
CureVac received 4 more outperform votes than Ventyx Biosciences when rated by MarketBeat users. Likewise, 55.26% of users gave CureVac an outperform vote while only 53.13% of users gave Ventyx Biosciences an outperform vote.
CureVac currently has a consensus target price of $21.00, indicating a potential upside of 129.51%. Ventyx Biosciences has a consensus target price of $55.40, indicating a potential upside of 60.77%. Given CureVac's higher probable upside, equities research analysts clearly believe CureVac is more favorable than Ventyx Biosciences.
CureVac has a beta of 2.89, meaning that its share price is 189% more volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of -0.35, meaning that its share price is 135% less volatile than the S&P 500.
Summary
CureVac beats Ventyx Biosciences on 8 of the 13 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools